Thermo Fisher Q1 Revenue Rises 6% to $11.01B; EPS Up and $3B Buyback
Thermo Fisher Scientific’s Q1 revenue rose 6% to $11.01 billion, GAAP EPS climbed 11% to $4.43 and adjusted EPS increased 6% to $5.44. It completed the acquisition of Clario, repurchased $3.0 billion of shares, raised its dividend by 10%, and announced collaborations with NVIDIA and SHL Medical.
1. Q1 Financial Performance
Thermo Fisher Scientific reported first quarter revenue of $11.01 billion, a 6% increase from $10.36 billion a year earlier. GAAP diluted EPS rose 11% to $4.43 and adjusted EPS grew 6% to $5.44, while GAAP operating margin improved to 16.9% from 16.6%. Organic revenue growth was 1%, reflecting steady underlying demand across life sciences and analytical markets.
2. Strategic Capital Deployment
During the quarter, the company finalized its acquisition of Clario, enhancing its endpoint data solutions portfolio. It repurchased $3.0 billion of common stock and increased its quarterly dividend by 10%, underscoring a commitment to returning capital to shareholders and strengthening its balance sheet.
3. Partnerships and Product Innovation
Thermo Fisher launched multiple high-impact instruments including the Glacios 3 Cryo-TEM and TSQ Certis mass spectrometer to broaden lab access and improve analytical throughput. The company also forged collaborations with NVIDIA to integrate AI into scientific instrumentation and with SHL Medical to deliver integrated sterile fill-finish and device assembly solutions.